Quest Diagnostics (DGX) EVP trades 26,165 shares under 10b5-1 plan

Rhea-AI Filing Summary

Quest Diagnostics EVP Catherine T. Doherty reported an option exercise and related share sales. On 02/13/2026 she exercised 26,165 non-qualified stock options at $112.17 per share, receiving the same number of common shares.

That day she sold 26,165 common shares in several open-market transactions at weighted average prices between $205.2072 and $209.1024, under a pre-established Rule 10b5-1 sales plan. After these transactions, she held 68,068 common shares directly and 4,503 shares indirectly through a 401(k)/deferred compensation plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doherty Catherine T.

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Regional Businesses

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M(1)		26,165	A	$112.17	94,233	D
Common Stock	02/13/2026		S(1)		10,573	D	$205.2072(2)	83,660	D
Common Stock	02/13/2026		S(1)		10,122	D	$206.3706(3)	73,538	D
Common Stock	02/13/2026		S(1)		3,500	D	$207.0822(4)	70,038	D
Common Stock	02/13/2026		S(1)		1,619	D	$208.2107(5)	68,419	D
Common Stock	02/13/2026		S(1)		351	D	$209.1024(6)	68,068	D
Common Stock								4,503(7)	I	401(k)/SDCP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$112.17	02/13/2026		M(1)			26,165	(8)	02/18/2030	Common Stock	26,165	$112.17	0	D

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $204.745 to $205.740. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $205.770 to $206.7489. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $206.770 to $207.675. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $207.810 to $208.600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $208.970 to $209.355. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

8. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Catherine T. Doherty	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DGX executive Catherine T. Doherty report?

Catherine T. Doherty reported exercising stock options and selling Quest Diagnostics common shares. She exercised 26,165 non-qualified stock options and sold the same number of shares in multiple open-market transactions on February 13, 2026 under a Rule 10b5-1 trading plan.

How many Quest Diagnostics (DGX) options did Catherine T. Doherty exercise?

She exercised 26,165 non-qualified stock options for Quest Diagnostics common stock. The options had an exercise price of $112.17 per share and were fully exercised on February 13, 2026, converting into 26,165 shares of common stock before the related sales took place.

How many Quest Diagnostics (DGX) shares did Catherine T. Doherty sell and at what prices?

She sold a total of 26,165 Quest Diagnostics common shares in several trades. Weighted average sale prices ranged from about $205.21 to $209.10 per share, with each sale code reported as an open-market or private transaction occurring on February 13, 2026.

How many Quest Diagnostics (DGX) shares does Catherine T. Doherty own after the reported transactions?

After the reported transactions, she held 68,068 Quest Diagnostics common shares directly. She also had an indirect holding of 4,503 shares through the company’s 401(k) and Supplemental Deferred Compensation Plan, based on information from the plan administrator.

Was Catherine T. Doherty’s Quest Diagnostics (DGX) stock sale pre-planned?

Yes. The filing states the option exercise and related stock sales were effected under a Rule 10b5-1 sales plan. Such plans allow insiders to pre-schedule trades, providing a structured way to sell shares over time under predetermined conditions.

What is Catherine T. Doherty’s role at Quest Diagnostics (DGX) in this Form 4?

In this Form 4, Catherine T. Doherty is identified as an officer of Quest Diagnostics, serving as Executive Vice President, Regional Businesses. The transactions reported reflect her personal direct and indirect holdings in the company’s common stock and related options.